# TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

> **NCT06598969** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fundación Pública Andaluza para la gestión de la Investigación en Sevilla** · enrollment: 58 (estimated)

## Conditions studied

- Myelodysplastic Syndromes
- Myeloid Leukemia, Acute

## Interventions

- **DRUG:** Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide

## Key facts

- **NCT ID:** NCT06598969
- **Lead sponsor:** Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2026-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06598969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06598969, "TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06598969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*